Votre navigateur est obsolète !

Pour une expériencenet et une sécurité optimale, mettez à jour votre navigateur. Mettre à jour maintenant


Benoît Serive

Marine pharmacognosy researcher

Benoît Serive
38 years old
Driving License
Nantes (44200) France
Professional Status
Just looking around
About Me
Laureate of the vocation award 2006
(Bleustein Blanchet Fundation)

Laureate 2013 - Marie Curie Outgoing Fellowship
OCEANCHArCoT programm

Member of the French Speaking Network of Metabolomics and Fluxomics

Member of the French Speaking Society of Pharmacognosy

Member of the American Society of Pharmacognosy

Member of the Association for the Sciences of Limnology and Oceanography

Reviewer for scientific peer-reviewed journals :
Marine Drugs, Algal Research

Invited Speaker at the 5th World Congress on Biotechnology (Valencia, Spain, June 2014)

In brief :

Voluntary, passionate and sensitive to human values​​, I want to use my skills to the search for molecules with high added value from marine biodiversity.

Golden prize of the most scholar, caring, and honest supervisor awarded to:

Prof. Ronald J. QUINN
(Eskitis Institute for Drug Discovery, Brisbane, Australia)

Mentor :

Emeritus Prof. Jean-Michel KORNPROBST
(University of Nantes, France)
  • OCEANCHArCoT program: OCEAN CHemodiversity Against Cell cycle Targets
  • Lead-Like Enhanced Fractions production and screening (HTS)
  • Evaluation of marine fractions from Great Barrier Reef organisms against biological model
  • NMR fingerprint dereplication
Detailed Description
  • Aim: Research of new marine inhibitors targeted against desease-relevant proteins kinases

    These latter are involved in various human pathologies such as cancer, neurodegenerative diseases or can be targeted to alter the life cycle of various parasites such as those responsible neglected parasitic diseases such as leishmaniasis and malaria. There are no physiological events not involving significant changes in protein phosphorylation. Therefore, PKs constitute currently the first class of targets used by pharmaceutical companies for the characterization of novel bioactive compounds. In a project intended to exploit the ocean biodiversity, Jean-Baptiste Charcot (1867-1936), a pioneer in oceanography established large collections of marine organisms. Taking this one step further, my project aims to source marine crude extracts from the Nature Bank collection (QLD, Australia), and from the unique Roscoff Culture Collection of microalgae (France) to identify new PK inhibitors. We will focus our analysis on PKs involved in the control of the cell division cycle (CDKs, TLKs and mitotic kinases such as Haspin and Auroras). The cellular effect of the selected inhibitors will be analysed on various cancer cell lines. This project will benefit from a new cutting edge technology will be used for the early screening of marine chemodiversity: bioaffinity (focused on PKs) mass spectrometry with a Bruker SolariX 12 Tesla FTMS. The lead-like enhanced fractions will be tested against various disease models and dereplicated in order to quickly identify bioactive molecules. Hit fractions will be produced in larger quantity before purification, characterization and pharmacological evaluation. In conclusion, OCEANCHArCoT will contribute, from Australia to France, to the research of marine bioactives to discover new therapeutic avenues to fight growing medical and social burdens such as cancer and Alzheimer’s disease.